Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
37.2M
-
Shares change
-
-4.1M
-
Total reported value, excl. options
-
$107M
-
Value change
-
-$21.9M
-
Put/Call ratio
-
0.22
-
Number of buys
-
37
-
Number of sells
-
-30
-
Price
-
$2.87
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q3 2023
92 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q3 2023.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.2M shares
of 56.1M outstanding shares and own 66.3% of the company stock.
Largest 10 shareholders include Bellevue Group AG (8.14M shares), NEA Management Company, LLC (4.45M shares), RA CAPITAL MANAGEMENT, L.P. (3.53M shares), T. Rowe Price Investment Management, Inc. (2.15M shares), Artal Group S.A. (2.05M shares), VANGUARD GROUP INC (1.96M shares), Verition Fund Management LLC (1.74M shares), BlackRock Inc. (1.4M shares), Point72 Asset Management, L.P. (1.12M shares), and JPMORGAN CHASE & CO (1.11M shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.